Medical education through expert conversations 🧬Podcasts, Interviews and Programs for clinicians 🩻 “Medicine Moves Through Shared Knowledge."
Joined October 2024
- Tweets510
- Following297
- Followers148
- Likes363
A look behind the scenes at conversations around the latest advances in breast cancer research and treatment. From new developments in care to perspectives on what’s ahead, there’s a lot to discuss.
Stay tuned for more conversations, perspectives and key takeaways.
Could DESTINY-Breast05 help address one of the biggest remaining challenges in HER2+ breast cancer?
Despite major advances in treatment, CNS metastases remain an important unmet need in HER2+ breast cancer.
Dr. Mothaffar Rimawi (@mfrimawi) reflects on the early CNS findings from DESTINY-Breast05, where the results appear numerically encouraging. He discusses the possibility that T-DXd could help reduce the risk of brain metastases, while emphasizing the need for longer follow-up before drawing conclusions.
What are your thoughts on the early CNS findings from DESTINY-Breast05?
Learn more here: communityhealth.media/series…
Can complete ctDNA clearance in SERENA-6 translate into longer survival for patients with HR+/HER2- advanced breast cancer?
Drs. Mabel Mardones (@mabelonc) and Anne O'Dea (@AnneODeaMD) point out that 50% of patients in SERENA-6 who switched early to the oral SERD camizestrant at the emergence of an ESR1 mutation achieved complete ctDNA clearance by 8 weeks, compared with just 2% of those who continued on their aromatase inhibitor. While phase 3 survival data are still maturing, both experts discuss why this level of molecular eradication is likely to correlate with overall survival.
Does seeing 50% complete ctDNA clearance make a difference in how you view early switching? Share your thoughts below. Learn more here: communityhealth.media/series…
Community Health Media retweeted
Why Cara Jade Myers Waited to Share Her Breast Cancer Diagnosis
▶️ Watch on YouTube - youtu.be/QKfoul__xC4
🎧 Listen on Spotify, Apple Podcasts, Amazon Music, CastBox & iHeartRadio
🎙️ @alisonhaislip @CHMediaHub
#BigCEnergy
Community Health Media retweeted
What Is Molecular Progression, and Why Catch It Early?
▶️ Watch the full Episode 10 on YouTube - youtu.be/5Z7a3HkDsG4?si=ALjh…
🎧 Listen on Spotify, Apple Podcasts, Amazon Music, CastBox & iHeartRadio - linkin.bio/breastfriendspodc…
🎙@JAMouabbi @PTarantinoMD @CHMediaHub
Community Health Media retweeted
I hate watching experimental therapeutics sessions where they say their drug is active in a wide range of “solid tumors” yet breast was excluded. We need new drugs too! Especially in #TNBC and Luminal B #BreastCancer . Please give us some non-TOPO-1 ADCs!!! #ESMO26
Community Health Media retweeted
🧠 CNS activity of a TROP2 ADC in a randomized phase 3. #ESMO26 LBA96: brain mets analysis of TROPION-Breast02, Dato-DXd vs chemo in 1L TNBC patients who are not IO candidates. 🧵 #bcsm
61 of 644 patients had asymptomatic, stable brain mets (30 untreated, 31 previously treated). 24 had measurable intracranial disease.
🙌🏻 Intracranial response:
ORR 62.5% vs 37.5%, including a complete response
12-week intracranial disease control 75% vs 50%
🙌🏻 CNS PFS 9.5 vs 2.6 mo, HR 0.27 (95% CI 0.13–0.56). Systemic PFS in the brain mets group: 7.7 vs 3.5 mo, HR 0.37.
The signal held in *untreated* brain mets: PFS HR 0.29, OS HR 0.35. That's the group where systemic options matter most.
Bottom line: Dato-DXd is a reasonable systemic choice for 1L TNBC with brain mets.
A historical HER2-negative result may not tell the whole story.
Dr. Sunil Badve highlights the importance of revisiting prior tissue samples or obtaining a new biopsy when appropriate to identify HER2-low and HER2-ultralow expression, helping ensure eligible patients are not overlooked for treatment with T-DXd.
Are you routinely reassessing HER2 status in your patients with metastatic breast cancer? 👇
Community Health Media retweeted
Pathologists are some of my favorite and most intelligent colleagues, and Dr. Badve is a pioneer in the field- I always listen to what he has to say!
HER2-low and HER2-ultralow breast cancers, traditionally classified as HER2-negative, now have a targeted option in trastuzumab deruxtecan (T-DXd).
Dr. Neil Iyengar (@Neil_Iyengar) and Dr. Sunil Badve explain why this shift is so remarkable, and why accurate HER2 testing and interpretation matter more than ever.
How has this changed the way you test and treat?
When is the right time to introduce T-DXd in HR+/HER2-low and HER2-ultralow metastatic breast cancer?
Dr. @Neil_Iyengar reflects on the DESTINY-Breast06 findings, which demonstrated improved progression-free survival with T-DXd compared with conventional chemotherapy, and what these results mean for bringing T-DXd earlier into the treatment sequence.
What are you using after endocrine-based therapy in your patients with HER2-low or HER2-ultralow disease? 👇
Community Health Media retweeted
🚨 #ESMO26 Lung Cancer: Top Ten by @OncoAlert 🫁
The abstracts our faculty picked as must-know from Madrid 👇
1️⃣ DeLLphi-305 (LBA3): tarlatamab + durvalumab, 1L maintenance in ES-SCLC
2️⃣ Krascendo 1 (LBA5): divarasib vs sotorasib/adagrasib in KRAS G12C NSCLC
3️⃣ SAFFRON (LBA6): osimertinib + savolitinib in EGFRm MET+ NSCLC post-osimertinib
4️⃣ OptiTROP-Lung04 (LBA67): final OS, sac-TMT vs chemo after EGFR-TKI
5️⃣ OptiTROP-Lung06 (LBA66): sac-TMT + pembro, 1L PD-L1-negative non-squamous NSCLC
6️⃣ PERSEE (2614O): pembro ± chemo, 1L PD-L1 ≥50%
7️⃣ SANOVO (LBA69): savolitinib + osimertinib, 1L EGFRm MET-overexpressed NSCLC
8️⃣ IFCT-2103 DIAL (2618RO): continue pembro vs observation at 6 months
9️⃣ PANKU-Lung01 (LBA71): iza-bren after third-generation EGFR TKI
🔟 SARON (2613O): consolidation radiotherapy in oligometastatic NSCLC
#lcsm #OncoAlert #MedTwitter
Pinging our OncoAlert Lung Cancer Faculty
@christine_lovly, @GlopesMd, @DrSanjayPopat, @StephenVLiu, @jillfeldman4, @UOzkerim, @DrMirallas, @MartinReck2 , @bmassutis @UmbertoMalapel1 , @CharuAggarwalMD
@peters_solange, @HenningWillers, @HHorinouchi, @BRicciutiMD, @PercyLeeMD, @bensolomon1, @Latinamd, @DrJNaidoo, @barlesi, @VanitaNoronha, @ChristianRolfo @Tony_Calles @s_couraud @marinagarassino @g_mountzios @BairdAM @barlesi @JFreemanDaily @Piuchagarrido @LeciaSequist @bensolomon1 @VanitaNoronha +@alexdrilon @JordiRemon @caliraf @JulienMazieres @TerriConneran
Community Health Media retweeted
We now have prospective data with TOPO1 ADC sequencing from:
- SATEEN (#ESMOBreast26)
- HER3-DXd (#ESMOBreast26)
- SWITCH (upcoming #ESMO26)
All validate prior retrospective data, showing that TOPO1 ADC resistance is not overcome by target switch.
New payloads urgently needed.
#ESMO26 | SWITCH – Phase II
In mBC progressing after ADC therapy, switching the target antigen while continuing with the same TOP1 inhibitor payload class resulted in ORRs of only 0–8.3%.
Although the sample size was small and the patient population heterogeneous, changing the target antigen alone does not appear sufficient to overcome resistance.
Community Health Media retweeted
🚨 ESMO 2026: 15 Trials That Could Change Oncology Practice!
From personalized cancer vaccines and bispecific antibodies to next-generation ADCs, major results are coming.
🔥 My Top 15 to Watch:
1. INTerpath-001 | Melanoma
2. SAFFRON | EGFR+ NSCLC
3. Krascendo 1 | KRAS G12C NSCLC
4. DeLLphi-305 | ES-SCLC
5. HARMONi-GI1 | Biliary
6. VOLGA | Bladder
7. DASL-HiCaP | Prostate
8. NATALEE | Breast
9. TRIO-US B-12 TALENT | Breast
10. ENERGIZE | Bladder
11. CLARITY-Gastric 01 | Gastric
12. KEYNOTE-C93 | Endometrial
13. KEYNOTE-B49 | Breast
14. LITESPARK-011 | RCC
15. SigVie-002 | NSCLC
📊 The big question: Which trials will deliver meaningful survival benefits and redefine standards of care?
Not every positive trial is practice-changing.
👨⚕️ Oncologists, which trial are you watching most closely?
#ESMO26 #Oncology #CancerResearch
@ASCO @oncoalert @myesmo @esmo_open
How much HER2 expression is enough to make a difference?
The DESTINY-Breast04 and DESTINY-Breast06 trials have changed how we think about HER2 expression in metastatic breast cancer, expanding treatment possibilities for patients with HER2-low and HER2-ultralow disease.
Dr. Sunil Badve uses an analogy of moss, grass, shrubs, and trees to explain how even very low levels of HER2 expression, once considered clinically insignificant, may still be relevant when identifying patients who could benefit from T-DXd.
How are you approaching treatment decisions for patients with HER2-low and HER2-ultralow disease? 👇
How long should patients stay on T-DXd + pertuzumab?
In DESTINY-Breast09, the median time to complete response was approximately 8 months, while the median time to maximum tumor reduction was around 11 months.
Dr. Irene Kang (@irenekangmd) discusses why these findings have changed how she thinks about treatment duration in first-line HER2+ metastatic breast cancer, particularly the importance of giving patients enough time to achieve their best response rather than transitioning to maintenance after just 6–8 cycles.
How are you approaching treatment duration with T-DXd + pertuzumab in your practice?
ESR1 mutations are more than a marker of endocrine resistance. They're actionable.
Drs. Jason Mouabbi (@JAMouabbi) and Erika Hamilton (@ErikaHamilton9) discuss the evolving treatment landscape for HR+/HER2− metastatic breast cancer, including the importance of repeat ESR1 testing and how different mechanisms of action may influence treatment decisions.
In the longer discussion, they take a closer look at vepdegestrant, how its PROTAC mechanism of action differs from oral SERDs, and how emerging insights into endocrine resistance may help shape more individualized treatment approaches.
Watch the full conversation to hear their perspectives on these evolving treatment considerations here: youtu.be/4VjgfVTa0hI?si=XzCd…
Community Health Media retweeted
For patients living with breast cancer, there is real reason for hope.
▶️ Watch the full Episode 10 on YouTube - youtu.be/5Z7a3HkDsG4?si=ALjh…
🎧 Listen on Spotify, Apple Podcasts, Amazon Music, CastBox & iHeartRadio - linkin.bio/breastfriendspodc…
🎙 @JAMouabbi @PTarantinoMD @CHMediaHub
How Are You Using Liquid Biopsy to Detect ESR1 Mutations?
When testing for ESR1 mutations, having a broader picture of the disease can help inform treatment decisions.
Dr. Erika Hamilton (@ErikaHamilton9) explains how liquid biopsy (ctDNA testing) can complement tissue NGS by detecting ESR1 mutations shed from different metastatic sites, offering additional insight into tumor biology when selecting subsequent endocrine therapy.
How are you approaching ESR1 mutation testing in your patients?
T-DXd Expands Treatment Options for HER2-Ultralow Breast Cancer
With T-DXd now an option for eligible patients with HER2-ultralow metastatic breast cancer, even very low levels of HER2 expression can make a difference in treatment selection.
Having another treatment option is a meaningful step forward for patients who previously had fewer choices.
What difference has T-DXd made for your patients with HER2-ultralow disease?